Clinical Trials Logo

Coronary Disease clinical trials

View clinical trials related to Coronary Disease.

Filter by:

NCT ID: NCT03266367 Not yet recruiting - Acute Kidney Injury Clinical Trials

Neutrophil Gelatinase Associated Liocalin in Predicting AKI in Coronary Artery Disease

Start date: September 15, 2017
Phase: N/A
Study type: Observational

The aim of this work is to assess the clinical significance of serum levels of neutrophil gelatinase-associated lipocalin (NGAL) to predict AKI in patients exposed to PCI.

NCT ID: NCT03197844 Not yet recruiting - Coronary Disease Clinical Trials

Study on Registration of Xinyuan Capsule

Start date: June 23, 2017
Phase: N/A
Study type: Observational

The purpose of this study is get to know what and how Xinyuan capsule in hospital results in drug-induced liver injury or adverse drug reactions from a cohort event monitoring as registration research.

NCT ID: NCT03189199 Not yet recruiting - Clinical trials for Coronary Heart Disease

A Registry Study on Safety Surveillance of Dazhuhongjingtian (a Chinese Medicine Injection) Used in China

Start date: June 19, 2017
Phase: N/A
Study type: Observational

The purpose of this study is to make a cohort event monitoring to see whether and how Dazhuhongjingtian injection in hospital results in adverse events or adverse drug reactions

NCT ID: NCT03146208 Not yet recruiting - Clinical trials for Coronary Artery Disease

Role of Endothelial Biomarkers in Patients With Coronary Artery Disease

Start date: July 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

Coronary artery disease is a contraction of the coronary arteries that prevent adequate blood supply to the heart muscle is called CAD. Usually caused by atherosclerosis, it may be advanced to the point where the heart muscle is injured due to lack of blood supply. Such damage may result in infarction, arrhythmias, and heart failure(1,2). Telomeres are short in circulating leucocytes in patients with coronary artery disease but the precise mechanism is not well-known (3). Telomere and telomerase are affected by cytomegalovirus (CMV) infection due to its effect on increasing the number of highly differentiated T cells that are characterized by shorter telomere length (TL) and lowered telomerase activity (TA). Both genetic and environmental factors have been connected with individual distinction in TL.Cardiovascular risk factors such as smoking, diabetes mellitus, hypertension, obesity, and stress have been considered to upsurge inflammation, oxidative stress, therefore accelerating TL shortening (1,2) It has also been observed that telomere loss in type 2 diabetic patients contributes to oxidative stress and endoplasmic reticulum stress while telomere shortening has also been proposed that it can serve as an independent risk factor of T2DM and it can measure disease progression(4). Moreover, telomeric length in peripheral blood mononuclear cells (PBMCs) is associated with the duration of disease and good glycemic control seems to be protective for telomeric loss (5). Growth differentiation factor-15 (GDF-15) is a member of the transforming growth factor (TGF)-β superfamily. GDF-15, recently identified as one of the new cardioprotective cytokines. It is highly expressed in cardiomyocytes, adipocytes, macrophages, endothelial cells, and vascular smooth muscle cells in normal and pathological condition. GDF-15 increases during tissue injury and inflammatory states and is associated with cardiometabolic risk(6). Dipeptidyl peptidase inhibitors (DPP4 -I) are called gliptins which increase the incretin levels and therefore prolong the post-prandial insulin action(7). Diana et al reported that In type 2 diabetic patients, leukocyte telomere was significantly shorter than control groups and was significantly elongated after intervention by sitagliptin(8). The common feature of all risk factors of CAD and T2DM imbalance between pro- and anti-oxidative factors in the organism with an increased production of reactive oxygen species (ROS).Nuclear factor erythroid-derived factor 2-related factor 2(Nrf2) is a family of transcription factors which plays an important role in protection against CVD and DM by regulating antioxidant enzymes in cells after ROS exposure (9). In our study, we will propose a model, which would provide the basis to establish a marker for chronic reactivation of CMV and shed more light into the pathophysiology of CMV infection in patients with CAD in relation to GDF-15 and NrF2 and their implications on disease progression. Ultimately, this would then enable us to identify patients at risk and develop novel strategies for future treatment and prevention of heart diseases in our country. In light of our project research, the question arises whether telomere length could represent a marker of chronic CMV reactivation and uncertainty their length will be modified by the effect of DPP-4 or not?

NCT ID: NCT03116438 Not yet recruiting - Clinical trials for Coronary Artery Disease

CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients

SOLDIER
Start date: June 16, 2017
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate the safety and performance of the CADence device by comparing it to the results obtained from standard coronary angiography. The CADence device collects acoustic (sound) data from locations on the chest for the purpose of identifying coronary artery turbulence, which may be indicative of coronary artery disease.

NCT ID: NCT03095469 Not yet recruiting - Heart Injuries Clinical Trials

Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

EODOPWCHD
Start date: August 20, 2017
Phase: Early Phase 1
Study type: Interventional

Coronary heart disease has a high incidence and high death rate. Percutaneous coronary intervention (PCI) is an important method for the treatment of coronary heart disease (CHD). However, PCI may cause myocardial cell injury and myocardial infarction 4 Type(MI4a, Type 4 a myocardial infarction related to PCI). Dexmedetomidine(Dex) is the only anesthetic which has sedative and analgesic effects. Dex currently has been widely used in perioperative management of various surgical.This study intends to verify the effect of heart protection of Dex in perioperative.

NCT ID: NCT03072121 Not yet recruiting - Clinical trials for Coronary Artery Disease(CAD)

Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Start date: June 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Shexiang Baoxin Pill is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

NCT ID: NCT03072082 Not yet recruiting - Clinical trials for Coronary Artery Disease(CAD)

Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization

Start date: June 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether Danlou Tablet is effective in the treatment of coronary artery disease not amenable to revascularization on the basis of western medicine therapy.

NCT ID: NCT03067402 Not yet recruiting - Clinical trials for Coronary Artery Disease

Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline

ROSSTAR
Start date: March 20, 2017
Phase: N/A
Study type: Interventional

The ROSSTAR trial is a pragmatic trial that will directly compare the strategies of routine and selective stress imaging testing (with radionuclide imaging (RNI)) late after PCI or CABG in asymptomatic patients. The study will be a single center trial based at the Jewish General Hospital (JGH), a McGill University teaching hospital (Montreal, Quebec). A total of 1100 patients who are either >5 years post-CABG or >2 years post-PCI will be randomized. Half of the patients will be randomized to a routine RNI testing, and the other half to selective RNI testing.

NCT ID: NCT03055910 Not yet recruiting - Clinical trials for Coronary Artery Disease

Fractional Flow Reserve Fax Registry

F(FR)²
Start date: March 1, 2017
Phase: N/A
Study type: Observational [Patient Registry]

The Fractional Flow Reserve Fax Registry is an investigator-initiated, real-world registry to analyze the use of fractional flow reserve (FFR) measurements in clinical practice in cardiac catheterization laboratories in Germany. The registry aims to collect the data of 2000 patients who underwent FFR recordings for clinical reasons. The main outcome parameter is the frequency of coronary revascularization following FFR. Secondary outcome parameters include the distribution of quantitative FFR results in clinical practice, the influence of intracoronary versus intravenous adenosine on the distribution of FFR results, the rate of complications as a result of FFR measurements, the average number of FFR wires needed per patient. Since the study will include a large number of patients who undergo i.c. administration of adenosine and a large number of patients who undergo i.v. administration of adenosine, it will be possible to analyze whether the route of adenosine administration is an independent predictor of the FFR result.